Menu
Logo

Professor Thierry Facon presents MAIA-study

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings

A phase 3 randomised study of daratumumab plus lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant.


CP-130012


DARZALEX® (DARATUMUMAB) short SPC, click here

CP-130489